NCT02080637View on ClinicalTrials.gov

Ambrisentan in Single Ventricle

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

July 20, 2017

Study Completion Date

August 20, 2017

Conditions
Hypoplastic Left Heart SyndromeHypoplastic Right-sided Heart Complex
Interventions
DRUG

Ambrisentan

Once daily oral dosing

OTHER

Placebo

Trial Locations (1)

27710

Duke Universtiy Hospital, Durham

All Listed Sponsors
lead

Kevin Hill

OTHER

NCT02080637 - Ambrisentan in Single Ventricle | Biotech Hunter | Biotech Hunter